Lv5
960 积分 2021-12-27 加入
Ivonescimab plus gemcitabine and cisplatin as first-line therapy for advanced biliary tract cancer: a multicenter, open-label phase 2 trial
28天前
已完结
Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial
29天前
已完结
Neoadjuvant toripalimab plus celecoxib versus toripalimab monotherapy for mismatch repair-deficient or microsatellite instability-high, locally advanced colorectal cancer (PICC-2): an open-label, multicentre, randomised, phase 2 trial
29天前
已完结
GPC3-specific dnTGFβRII-armoured CAR T cells for hepatocellular carcinoma
1个月前
已完结
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer
1个月前
已完结
KRAS-G12D inhibitor HRS-4642 plus chemotherapy in advanced KRASG12D-mutant pancreatic cancer: a phase 1b/2 trial
1个月前
已完结
Long-Term Prognostic Analysis of Chemoradiation Therapy Versus Chemotherapy after D2 Resection for High-Risk Gastric Cancer: Results From a Prospective Randomized Control Study
1个月前
已完结
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
2个月前
已完结
Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC
2个月前
已完结
皖公网安备34019202002308
